We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Genocea to Initiate a Phase I/II Oncology Study on GEN-011
Read MoreHide Full Article
Genocea Biosciences, Inc. announced that the FDA accepted its investigational new drug (“IND”) application for its neoantigen-specific cell therapy candidate, GEN-011. The acceptance of the IND application will allow the company to initiate a phase I/IIa study, which will evaluate GEN-011 in certain cancer patients who have failed standard-of-care checkpoint inhibitor therapy.
The company plans to enroll 24 patients across several tumor types in two cohorts to evaluate safety, T cell proliferation and persistence as well as clinical activity of GEN-011. Patients in one cohort of the study will be administered multiple low doses of GEN-011 with low-dose IL-2 and without lymphodepletion. In the other cohort, patients will be administered a single GEN-011 dose after lymphodepletion and a high dose of IL-2.
Please note that the FDA had placed the IND for GEN-011 under clinical hold in July due to requirement of additional information pertaining to certain third-party reagents used in the GEN-011 manufacturing process.
Genocea’s shares have gained 5.6% on Sep 22 following the news. Shares of the company have increased 18.4% so far this year against the industry’s decrease of 7.5%.
Genocea is focused on developing personalized cancer immunotherapies in multiple tumor types designed to improve upon the limitations of tumor-infiltrating lymphocytes (“TIL”) and T Cell Receptor (“TCR”) therapies, using its unique ATLAS platform. The company believes that GEN-011 has the potential to offer efficacy, accessibility and cost advantages to patients.
Apart from GEN-011, the company is currently developing another ATLAS-enabled program, GEN-009, which is a neoantigen vaccine, in a two-part phase I/IIa study. The study is evaluating combination of GEN-009 and immune checkpoint inhibitor-based regimens in advanced solid tumors. Data from the Part A of the study, presented in July, showed that at one-year of median follow-up seven out of eight patients treated with GEN-009 were without disease progression. Preliminary data from five patients in Part B of the study, presented in July, demonstrated that two of the first five patients achieved complete response and three experienced partial response. Additional immunogenicity and clinical data from the remaining 10 patients in the Part B is expected to announced later this year.
Based on these data, the company believes that addition of GEN-009 to standard-of-care immunotherapy regimens will likely boost the effectiveness of immune checkpoint inhibitor therapy in patients with advanced disease.
In May, the company signed a material transfer agreement and exclusive license option with Japan-based Shionogi to develop a novel HSV-2 vaccine. Genocea will be eligible to receive upfront payment, regulatory and sales milestones, as well as tiered royalties, if Shinogi chooses to exercise its option.
Genocea currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma/biotech sector include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics and Repligen Corporation (RGEN - Free Report) . While Emergent and Horizon sport a Zacks Rank #1 (Strong Buy), Repligen carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have moved 55.6% north for 2020 and 37.3% for 2021 over the past 60 days. The stock has soared 86.7% so far this year.
Horizon’s earnings per share estimates have moved up 49.7% for both 2020 and 2021 over the past 60 days. The company’s shares have increased 115.9% year to date.
Repligen’s earnings estimates have been revised 13.3% upward for 2020 and 7.6% for 2021 over the past 60 days. The stock has gained 55.6% so far this year.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Genocea to Initiate a Phase I/II Oncology Study on GEN-011
Genocea Biosciences, Inc. announced that the FDA accepted its investigational new drug (“IND”) application for its neoantigen-specific cell therapy candidate, GEN-011. The acceptance of the IND application will allow the company to initiate a phase I/IIa study, which will evaluate GEN-011 in certain cancer patients who have failed standard-of-care checkpoint inhibitor therapy.
The company plans to enroll 24 patients across several tumor types in two cohorts to evaluate safety, T cell proliferation and persistence as well as clinical activity of GEN-011. Patients in one cohort of the study will be administered multiple low doses of GEN-011 with low-dose IL-2 and without lymphodepletion. In the other cohort, patients will be administered a single GEN-011 dose after lymphodepletion and a high dose of IL-2.
Please note that the FDA had placed the IND for GEN-011 under clinical hold in July due to requirement of additional information pertaining to certain third-party reagents used in the GEN-011 manufacturing process.
Genocea’s shares have gained 5.6% on Sep 22 following the news. Shares of the company have increased 18.4% so far this year against the industry’s decrease of 7.5%.
Genocea is focused on developing personalized cancer immunotherapies in multiple tumor types designed to improve upon the limitations of tumor-infiltrating lymphocytes (“TIL”) and T Cell Receptor (“TCR”) therapies, using its unique ATLAS platform. The company believes that GEN-011 has the potential to offer efficacy, accessibility and cost advantages to patients.
Apart from GEN-011, the company is currently developing another ATLAS-enabled program, GEN-009, which is a neoantigen vaccine, in a two-part phase I/IIa study. The study is evaluating combination of GEN-009 and immune checkpoint inhibitor-based regimens in advanced solid tumors. Data from the Part A of the study, presented in July, showed that at one-year of median follow-up seven out of eight patients treated with GEN-009 were without disease progression. Preliminary data from five patients in Part B of the study, presented in July, demonstrated that two of the first five patients achieved complete response and three experienced partial response. Additional immunogenicity and clinical data from the remaining 10 patients in the Part B is expected to announced later this year.
Based on these data, the company believes that addition of GEN-009 to standard-of-care immunotherapy regimens will likely boost the effectiveness of immune checkpoint inhibitor therapy in patients with advanced disease.
In May, the company signed a material transfer agreement and exclusive license option with Japan-based Shionogi to develop a novel HSV-2 vaccine. Genocea will be eligible to receive upfront payment, regulatory and sales milestones, as well as tiered royalties, if Shinogi chooses to exercise its option.
Genocea Biosciences, Inc. Price
Genocea Biosciences, Inc. price | Genocea Biosciences, Inc. Quote
Zacks Rank & Stocks to Consider
Genocea currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the pharma/biotech sector include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics and Repligen Corporation (RGEN - Free Report) . While Emergent and Horizon sport a Zacks Rank #1 (Strong Buy), Repligen carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have moved 55.6% north for 2020 and 37.3% for 2021 over the past 60 days. The stock has soared 86.7% so far this year.
Horizon’s earnings per share estimates have moved up 49.7% for both 2020 and 2021 over the past 60 days. The company’s shares have increased 115.9% year to date.
Repligen’s earnings estimates have been revised 13.3% upward for 2020 and 7.6% for 2021 over the past 60 days. The stock has gained 55.6% so far this year.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>